Mizuho lowered the firm’s price target on Edwards Lifesciences to $90 from $102 and keeps a Buy rating on the shares. The analyst lower targets on several medical technology names ahead of the Q3 earnings season to reflect inputs from hospital/physician surveys and key opinion leader channel checks. The target drops account for the sharp intra-quarter contraction driven in part by GLP-1 risk concerns, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences initiated with a Market Perform at Leerink
- Edwards Lifesciences price target lowered to $83 from $105 at Truist
- Edwards Lifesciences put volume heavy and directionally bearish
- Citi cuts Edwards Lifesciences target, opens ‘negative catalyst watch’
- Edwards Lifesciences (EW) Under the Radar of EU Antitrust Regulators
